Biologics in the treatment of psoriasis and emerging new therapies in the pipeline

Lauren L Levy*, Shayna M Solomon*, Jason J Emer Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA*Both authors contributed equally to this work and represent co-first authorshipAbstract: Elucidation of the immunopathogenesis of psoriasis has led to the discovery of novel b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Levy LL, Solomon SM, Emer JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/b88dbb1a60aa491da0adb230dd5695a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b88dbb1a60aa491da0adb230dd5695a8
record_format	dspace
spelling	oai:doaj.org-article:b88dbb1a60aa491da0adb230dd5695a82021-12-02T06:53:45ZBiologics in the treatment of psoriasis and emerging new therapies in the pipeline2230-326Xhttps://doaj.org/article/b88dbb1a60aa491da0adb230dd5695a82012-06-01T00:00:00Zhttp://www.dovepress.com/biologics-in-the-treatment-of-psoriasis-and-emerging-new-therapies-in--a10146https://doaj.org/toc/2230-326XLauren L Levy, Shayna M Solomon, Jason J Emer Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA*Both authors contributed equally to this work and represent co-first authorshipAbstract: Elucidation of the immunopathogenesis of psoriasis has led to the discovery of novel biologic agents for the treatment of moderate-to-severe plaque psoriasis. There are currently five biologic agents approved by the US Food and Drug Administration for psoriasis which have proven to be quite efficacious in clinical trials and in post-marketing and clinical experience. As more details are uncovered about the immunologic pathways involved in initiation and maintenance of this disease, there will be an increasing development and marketing of novel therapeutics. It is crucial to understand the immunopathogenesis of psoriasis and the mechanisms of these novel agents in order to to treat the psoriatic population effectively and mitigate disease burden. This article reviews the currently approved biologics for the treatment of psoriasis, with emphasis on efficacy and safety. There are countless therapies currently in the research pipeline, with mechanisms ranging from receptor antagonism to signal transduction pathway inhibition. The initial trials and future studies involving these new agents are also reviewed. As therapeutics escalate through the research pipeline, the management and treatment of psoriasis will likely become more manageable for practitioners and patients.Keywords: psoriasis, treatment, biologicsLevy LLSolomon SMEmer JJDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2012, Iss default, Pp 29-43 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Levy LL Solomon SM Emer JJ Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
description	Lauren L Levy, Shayna M Solomon, Jason J Emer Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA*Both authors contributed equally to this work and represent co-first authorshipAbstract: Elucidation of the immunopathogenesis of psoriasis has led to the discovery of novel biologic agents for the treatment of moderate-to-severe plaque psoriasis. There are currently five biologic agents approved by the US Food and Drug Administration for psoriasis which have proven to be quite efficacious in clinical trials and in post-marketing and clinical experience. As more details are uncovered about the immunologic pathways involved in initiation and maintenance of this disease, there will be an increasing development and marketing of novel therapeutics. It is crucial to understand the immunopathogenesis of psoriasis and the mechanisms of these novel agents in order to to treat the psoriatic population effectively and mitigate disease burden. This article reviews the currently approved biologics for the treatment of psoriasis, with emphasis on efficacy and safety. There are countless therapies currently in the research pipeline, with mechanisms ranging from receptor antagonism to signal transduction pathway inhibition. The initial trials and future studies involving these new agents are also reviewed. As therapeutics escalate through the research pipeline, the management and treatment of psoriasis will likely become more manageable for practitioners and patients.Keywords: psoriasis, treatment, biologics
format	article
author	Levy LL Solomon SM Emer JJ
author_facet	Levy LL Solomon SM Emer JJ
author_sort	Levy LL
title	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
title_short	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
title_full	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
title_fullStr	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
title_full_unstemmed	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
title_sort	biologics in the treatment of psoriasis and emerging new therapies in the pipeline
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/b88dbb1a60aa491da0adb230dd5695a8
work_keys_str_mv	AT levyll biologicsinthetreatmentofpsoriasisandemergingnewtherapiesinthepipeline AT solomonsm biologicsinthetreatmentofpsoriasisandemergingnewtherapiesinthepipeline AT emerjj biologicsinthetreatmentofpsoriasisandemergingnewtherapiesinthepipeline
_version_	1718399714850766848

Biologics in the treatment of psoriasis and emerging new therapies in the pipeline

Ejemplares similares